- Home
- GBCI vs AXSM Comparison
GBCI vs AXSM Comparison
Compare GBCI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBCI
- AXSM
- Stock Information
- Founded
- GBCI 1955
- AXSM 2012
- Country
- GBCI United States
- AXSM United States
- Employees
- GBCI N/A
- AXSM N/A
- Industry
- GBCI Major Banks
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GBCI Finance
- AXSM Health Care
- Exchange
- GBCI Nasdaq
- AXSM Nasdaq
- Market Cap
- GBCI 4.8B
- AXSM 5.1B
- IPO Year
- GBCI N/A
- AXSM 2015
- Fundamental
- Price
- GBCI $41.47
- AXSM $105.16
- Analyst Decision
- GBCI Hold
- AXSM Strong Buy
- Analyst Count
- GBCI 4
- AXSM 15
- Target Price
- GBCI $53.00
- AXSM $170.20
- AVG Volume (30 Days)
- GBCI 645.7K
- AXSM 612.2K
- Earning Date
- GBCI 07-17-2025
- AXSM 05-05-2025
- Dividend Yield
- GBCI 3.18%
- AXSM N/A
- EPS Growth
- GBCI 7.02
- AXSM N/A
- EPS
- GBCI 1.87
- AXSM N/A
- Revenue
- GBCI $827,816,000.00
- AXSM $432,157,000.00
- Revenue This Year
- GBCI $9.03
- AXSM $63.30
- Revenue Next Year
- GBCI $14.29
- AXSM $61.15
- P/E Ratio
- GBCI $22.19
- AXSM N/A
- Revenue Growth
- GBCI 8.47
- AXSM 72.16
- 52 Week Low
- GBCI $34.48
- AXSM $64.11
- 52 Week High
- GBCI $60.67
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- GBCI 47.68
- AXSM 45.61
- Support Level
- GBCI $40.91
- AXSM $101.41
- Resistance Level
- GBCI $41.85
- AXSM $106.77
- Average True Range (ATR)
- GBCI 0.84
- AXSM 3.18
- MACD
- GBCI -0.10
- AXSM -0.23
- Stochastic Oscillator
- GBCI 29.93
- AXSM 39.33
About GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.